- DHL Group has committed €2 billion over five years to strengthen logistics capabilities in the Life Sciences & Healthcare sector globally.
- €500 million of the investment will support expansion across Asia Pacific, including new facilities in Singapore, Malaysia, and Korea.
DHL Group has announced a strategic investment of €2 billion over the next five years to enhance its logistics operations in the Life Sciences & Healthcare (LSH) sector. The initiative is part of the Group’s “Strategy 2030” and aims to build integrated, resilient supply chain and logistics solutions tailored to the needs of the global healthcare industry.
Of the total investment, 50% will be directed to the Americas, 25% to Asia Pacific, and 25% to the EMEA region. The company plans to bolster infrastructure across storage, fulfilment, distribution, shipping, and last-mile delivery, with a focus on GDP-certified Pharma Hubs and cold chain capacity. The Asia Pacific region will see €500 million invested, with new developments planned in Singapore, Malaysia, and Korea.
The move is designed to address rising demand in key areas such as clinical trials, biopharma, and cell and gene therapies. Investments will also include ultra-low temperature storage, temperature-controlled vehicles, and upgraded packaging technologies to support complex, cross-border supply chains.
As part of the initiative, the Group has introduced a new sector brand – DHL Health Logistics – to unify its offerings under one umbrella. This brand will offer customers end-to-end visibility, regulatory compliance, and reliable product delivery across borders. DHL’s acquisition of clinical trials courier CRYOPDP complements this strategy.
“Similar to DHL Group’s purpose of ‘Connecting people, improving lives,’ our strategic investment in Life Sciences & Healthcare is driven by our customers’ mission: delivering essential, often life-saving products to people in need,” said Oscar de Bok, CEO of DHL Supply Chain.
Currently, DHL operates nearly 600 sites across 130 countries for LSH logistics, with over 2.5 million square metres of temperature-controlled space. The company generated over €5 billion in LSH revenue in 2024 and anticipates another €5 billion in incremental revenue by 2030 through this investment.